May 07, 2026 8:30am EDT Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Apr 23, 2026 9:00am EDT Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Apr 15, 2026 9:00am EDT Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Mar 18, 2026 8:30am EDT Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 02, 2026 8:30am EST Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Jan 12, 2026 8:30am EST Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Dec 22, 2025 10:15am EST Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dec 02, 2025 8:00am EST Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Nov 11, 2025 8:45am EST Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
